FDA Approves New Cholesterol Medication Inclisiran, Offering Alternative to Statins

The U.S. Food and Drug Administration (FDA) has approved Inclisiran, a novel daily cholesterol-lowering medication, marking a significant advancement in treating high LDL cholesterol, according to a July 2023 FDA announcement. Unlike traditional statins, which inhibit cholesterol production in the liver, Inclisiran targets a different biological pathway, offering potential benefits for patients who do not achieve sufficient results with existing therapies.

How Inclisiran Differs from Statins

Inclisiran belongs to a class of drugs known as small interfering RNA (siRNA) therapeutics. It works by silencing a specific gene, PCSK9, which regulates LDL cholesterol levels in the blood. This mechanism contrasts with statins, which block an enzyme involved in cholesterol synthesis. The drug is administered via a monthly injection, though it is taken orally in a daily pill form, according to the FDA’s prescribing information.

“Inclisiran represents a paradigm shift in cholesterol management,” said Dr. Robert Eckel, a professor of medicine at the University of Colorado, in a statement to MedPage Today. “By targeting PCSK9, it provides an alternative for patients who may not tolerate statins or require additional lipid-lowering strategies.”

Clinical Trial Results and Efficacy

Results from the ORION-10 and ORION-11 trials, published in the New England Journal of Medicine, demonstrated that Inclisiran reduced LDL cholesterol by 41% to 47% over 18 months. These trials involved over 4,000 participants with a history of cardiovascular disease or diabetes. The drug was generally well-tolerated, with common side effects including injection-site reactions and mild fatigue, as reported by the FDA.

“The magnitude of LDL reduction seen with Inclisiran is comparable to that of PCSK9 inhibitors, but with a more convenient dosing schedule,” said Dr. Christie Ballantyne, a cardiologist at Baylor College of Medicine, in a Reuters interview. “This could improve long-term adherence for patients.”

Who Might Benefit from Inclisiran?

The FDA has approved Inclisiran for adults with a history of cardiovascular disease or diabetes who require additional LDL cholesterol reduction beyond statin therapy. It is not recommended for patients with severe liver disease or those taking certain medications that interact with the drug, per the FDA’s guidelines.

Patients with familial hypercholesterolemia, a genetic condition that causes extremely high LDL levels, may also find Inclisiran beneficial. “For individuals with this condition, Inclisiran could be a game-changer,” said Dr. Sarah Deeb, a lipidologist at the Cleveland Clinic, in a Medical News Today article. “It addresses a critical unmet need in this population.”

What This Means for Patients and Healthcare Providers

The approval of Inclisiran expands treatment options for managing cholesterol, particularly for patients who cannot tolerate statins or require more aggressive intervention. However, cost and insurance coverage remain concerns. According to a Statista analysis, Inclisiran is expected to be priced similarly to existing PCSK9 inhibitors, which can exceed $14,000 annually.

Healthcare providers are encouraged to evaluate patients’ individual risk factors and treatment goals before prescribing Inclisiran. “This drug is not a replacement for lifestyle changes like diet and exercise,” warned the American Heart Association in a statement. “It should be used as part of a comprehensive approach to cardiovascular health.”

Future Outlook

As Inclisiran becomes available, ongoing real-world data will be critical to assessing its long-term safety and effectiveness. The FDA has also approved a second siRNA drug, Tafamidis, for treating transthyretin amyloidosis, signaling growing interest in RNA-based therapies. For now, Inclisiran offers a promising new tool in the fight against cardiovascular disease, with potential to improve outcomes for millions of patients.